Drugs for Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 136)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Ritonavir |
Approved, Investigational |
Phase 4 |
|
155213-67-5 |
392622 |
|
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
| 2 |
|
Efavirenz |
Approved, Investigational |
Phase 4 |
|
154598-52-4 |
64139 |
|
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
Bristol-myers squibb brand OF efavirenz
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
Du pont brand OF efavirenz
efavirenz
Efavirenz
|
Éfavirenz
Efavirenz (JAN/INN)
Efavirenz, (R)-isomer
efavirenz, (S)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
EFZ
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
Merck sharp and dohme brand OF efavirenz
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MLS000759465
MLS001424087
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
United drug brand OF efavirenz
ZINC02020233
zoxazin-2-one
|
|
| 3 |
|
Lopinavir |
Approved |
Phase 4 |
|
192725-17-0 |
92727 |
|
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
| 4 |
|
Emtricitabine |
Approved, Investigational |
Phase 4 |
|
143491-57-0 |
60877 |
|
Synonyms:
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(−)-2'-deoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(−)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-Emtricitabine
(-)-FTC
(−)-FTC
(−)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-Î’-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
524W91
5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
|
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
AC1L1U3I
AC1Q4KUB
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
BW 1592
BW 524W91
BW524W91
BW-524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
dOTFC
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
Racivir
RCV
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
|
|
| 5 |
|
Saquinavir |
Approved, Investigational |
Phase 4 |
|
127779-20-8 |
60787 |
|
Synonyms:
(2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S)-3-(Tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediimidate
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
127779-20-8
1hxb
2fgu
2fgv
AB00514056
AC-16711
AC1L9ATC
AKOS000280831
Ambap127779-20-8
BIDD:GT0323
BIDD:PXR0010
BPBio1_001373
BRD-K09963420-066-03-4
BSPBio_001248
CHEBI:45279
CHEMBL114
CID441243
CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE
D00429
Fortovase
Fortovase (TN)
Fortovase(TM)
Invirase
Invirase(TM)(monomesylate)
|
LS-187081
MLS001195635
MLS001304735
MolPort-000-883-824
Monomethanesulfonate, saquinavir
NCGC00091469-02
NSC722663
Prestwick0_001114
Prestwick1_001114
Prestwick2_001114
Prestwick3_001114
QNC-ASN-HPH-DIQ-NTB
Ro 318959
Ro 31-8959
Ro-31-8959
ROC
saguinavir
Saquinavir
SAQUINAVIR
Saquinavir (JAN/USP/INN)
Saquinavir mesylate
Saquinavir monomethanesulfonate
Saquinivir
Sequinavir
SMR000469157
SPBio_003114
SQV
|
|
| 6 |
|
Stavudine |
Approved, Investigational |
Phase 4 |
|
3056-17-5 |
18283 |
|
Synonyms:
1-(2,3-Dideoxy-b-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3056-17-5
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
AC1L2BQ9
AC1Q6BSH
AC-5263
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY27857
BMY-27857
Bristol-myers brand OF stavudine
Bristol-Myers Brand of Stavudine
Bristol-myers squibb brand OF stavudine
Bristol-Myers Squibb Brand of Stavudine
BRN 0618327
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
d4T
D4T & GM-CSF
D4TMBY-27857-3
DB00649
ddeThd
ddeTyd
Dideoxydidehydrothymidine
Estavudina
|
Estavudina [INN-Spanish]
EU-0100336
FT-0082665
HMS2051O20
HSDB 7338
Lopac0_000336
LS-1160
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
sanilvudine
Sanilvudine
Sanilvudine (JAN)
SMR000058350
SMR000673569
Stavudin
stavudine
Stavudine
Stavudine (USAN/INN)
Stavudine [Usan:Ban:Inn]
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine, monosodium salt
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
STK801888
STV
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
Zent
Zerit
Zerit (TN)
Zerit Xr
Zerit XR
Zerit(TM)
Zerut XR
ZINC00137884
|
|
| 7 |
|
Didanosine |
Approved |
Phase 4 |
|
69655-05-6 |
50599 |
|
Synonyms:
149409-57-4
2',3' Dideoxyinosine
2,3-dideoxyinosine
2,3-Dideoxyinosine
2',3'-Dideoxyinosine
2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor
2',3'-Dideoxyinosine & Interferon-.alpha.
2',3'-Dideoxyinosine & sCD4(soluble recombinant protein)
2',3'-Dideoxyinosine (AIDS Initiative)
2',3'-Dideoxyinosine (ddI)
2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine
2'3'-DIDEOXYINOSINE
2DI
3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine
69655-05-6
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
AC-12026
AC1L19ET
AC1L3OPK
Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
Bio-0685
BMY 40900
BMY-40900
Bristol myers brand OF didanosine
Bristol myers squibb brand OF didanosine
Bristol-myers brand OF didanosine
Bristol-myers squibb brand OF didanosine
BRN 3619529
C06953
C083832
CCRIS 805
CHEBI:490877
CHEMBL1460
CID119381
CID50599
CPD000058576
D00296
D2I
D3066
DB00900
DB02392
ddI
DDI
ddI & GM-CSF
ddI & IFN-.alpha.
ddI & sCD4(rsCD4)
DdI (antiviral)
|
ddI + d4T combination
DDI and rIFN.alpha.2
ddIno
DdIno
Didanosina
Didanosina [INN-Spanish]
didanosine
Didanosine
Didanosine (JAN/USAN/INN)
Didanosine and Interferon-.alpha.-2
Didanosinum
Didanosinum [INN-Latin]
Dideoxyinosine
DIDEOXYINOSINE
Dideoxyinosine (DDI)
DRG-0016
DS-4152 & ddI
FT-0082664
HMS2051J11
HMS2089N20
HSDB 6548
Hypoxanthine ddN
Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2
Intron A & Videx
KS-1049
Listera ovata agglutinin & 2',3'-Dideoxyinosine
LOA & ddI
MLS000759469
MLS001055350
MLS001424118
MLS002154216
MolPort-002-507-371
MolPort-002-885-819
N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride
N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride
NCGC00090691-01
NCGC00159514-02
NCGC00159514-03
NCGC00164280-01
NE 100
NE-100
NSC 612049
NSC612049
NSC-612049
PC-SOD+ddI
S1702_Selleck
SAM001246673
SMR000058576
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine
UNII-K3GDH6OH08
Videx
Videx (TN)
Videx EC
Videx EC(TM)(slow-release capsules)
Videx(TM)
ZINC13597823
|
|
| 8 |
|
Amprenavir |
Approved, Investigational |
Phase 4 |
|
161814-49-9 |
65016 |
|
Synonyms:
(3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid
(3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate
(3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate
[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
{3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER
141W94
161814-49-9
1hpv
1t7j
4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
AC1L22EW
AC1Q5X5K
Agenerase
Agenerase (TM)
Agenerase (TN)
AKOS000280844
AMP
amprenavir
Amprenavir
Amprénavir
Amprenavir (JAN/USAN/INN)
Amprenavir [USAN]
amprenavir[usan]
Amprenavirum
AMV
APV
BIDD:GT0398
C08086
|
C25H35N3O6S
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA)
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin( HHA)
CHEBI:40050
CHEMBL116
CID65016
D00894
DB00701
DRG-0258
FT-0082731
Glaxo wellcome brand OF amprenavir
GlaxoSmithKline brand OF amprenavir
GNA & Amprenavir
HHA & Amprenavir
HMS2090N10
HSDB 7157
KVX-478
LS-173559
MolPort-000-883-856
NCGC00159461-02
NCGC00159461-03
Prozei
S1639_Selleck
Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate
UNII-5S0W860XNR
Vertex
Vertex VX478
VX 478
VX478
VX-478
ZINC03809192
|
|
| 9 |
|
Tipranavir |
Approved, Investigational |
Phase 4 |
|
174484-41-4 |
65027 |
|
Synonyms:
174484-41-4
1d4y
2o4l
2o4n
2o4p
AC1L22FH
AC1Q4JPW
Aptivus
Aptivus (Boehringer Ingelheim)
Aptivus (TN)
Aptivus(TM)
CHEMBL222559
CID65027
D08605
DB00932
|
MolPort-003-850-561
N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulphonamide
PNU 140690
PNU-140690
PNU-140690E
tipranavir
Tipranavir
Tipranavir (INN)
TPV
U 140690
U-140690
UNII-ZZT404XD09
|
|
| 10 |
|
Indinavir |
Approved |
Phase 4 |
|
150378-17-9 |
5362440 |
|
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
CHEBI:44032
Compound J
|
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, sulfate (1:1)
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
Sulfate, indinavir
UNII-9MG78X43ZT
|
|
| 11 |
|
Enfuvirtide |
Approved, Investigational |
Phase 4 |
|
159519-65-0 |
16130199 |
|
Synonyms:
262434-79-7
C105196
Dp 178
DP178
Enfuvirtida
Enfuvirtide
Enfuvirtide [USAN]
Fuzeon
HSDB 7341
LS-183961
|
N-Acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histadyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide
Pentafuside
peptide T20
Roche brand of pentafuside
T 20
T 20 (peptide)
T-20
T-20 cpd
T20 peptide
UNII-19OWO1T3ZE
|
|
| 12 |
|
Nevirapine |
Approved |
Phase 4 |
|
129618-40-2 |
4463 |
|
Synonyms:
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2hny
AC1L1I81
AC-643
BI RG 587
BIDD:GT0326
Bio-0789
BIRG 0587
BIRG 587
BIRG-0587
BIRG587
BIRG-587
BI-RG-587
BI-RG-587 & CD4-IgG
C07263
C15H14N4O
Cahill May Roberts Brand of Nevirapine
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
D00435
D019829
DB00238
DB08311
Hemihydrate, nevirapine
HMS2051J09
HSDB 7164
|
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
Nevirapina
nevirapine
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Nevirapine anhydrous
Nevirapine hemihydrate
Nevirapine, anhydrous
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
|
|
| 13 |
|
Nelfinavir |
Approved |
Phase 4 |
|
159989-64-7 |
64143 |
|
Synonyms:
(3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
159989-64-7
159989-65-8 (monomethane sulfonate (salt))
1ohr
1UN
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
AC1L20J6
AC-20032
AG 1343
ag1343
AG1343
AG1343 (*Mesylate salt*)
AG1346
Agouron brand OF nelfinavir mesylate
AKOS000280862
BIDD:GT0395
BIDD:PXR0143
C07257
C32H45N3O4S
CHEMBL584
CID64143
D08259
DB00220
LS-85417
Mesylate, nelfinavir
Met-SDF-1.beta. & Nelfinavir
Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir
|
MLS001195634
MLS001304729
MolPort-000-883-833
MolPort-002-885-844
Monomethane sulfonate, nelfinavir
NCGC00090782-03
NCGC00090782-04
nelfinavir
Nelfinavir
Nelfinavir (INN)
Nelfinavir [BAN:INN]
Nelfinavir [INN:BAN]
Nelfinavir mesylate
NELFINAVIR MESYLATE AG1343
Nelfinavir monomethane sulfonate
Nelfinavir Monomethane Sulfonate
NFV
NLF
NSC722664
NSC747167
Roche brand OF nelfinavir mesylate
SMR000596515
Sulfonate, nelfinavir monomethane
UNII-HO3OGH5D7I
Viracept
Viracept (TM)(*Mesylate salt*)
Viracept (TN)
VRX496
|
|
| 14 |
|
Pioglitazone |
Approved, Investigational |
Phase 4 |
|
111025-46-8 |
4829 |
|
Synonyms:
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
Actos
Actos (TN)
Actost
AD 4833
AD-4833
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
HSDB 7322
|
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
nchembio790-comp10
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
pioglitazone (INN)
Pioglitazone [Ban:Inn]
Pioglitazone [BAN:INN]
Pioglitazone [INN:BAN]
pioglitazone HCl
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazone Hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
SPBio_001897
Spectrum_001623
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
U 72107
U 72107A
U72,107A
U-72107
UNII-X4OV71U42S
Zactos
|
|
| 15 |
|
Zalcitabine |
Approved, Investigational |
Phase 4 |
|
7481-89-2 |
24066 |
|
Synonyms:
.beta.-D-2',3'-Dideoxycytidine
.beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
.beta.-D-DDC
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine
16803P
2',3' Dideoxycytidine
2,3-dideoxycytidine
2',3'-Dideoxycytidine
2',3'-DIDEOXYCYTIDINE
2',3'-Dideoxycytidine & Interferon.alpha.
2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate)
2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
36775_FLUKA
3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
5-25-14-00313 (Beilstein Handbook Reference)
7481-89-2
AC1L2N6R
AC-824
bmse000712
BPBio1_001378
BRN 0654956
BSPBio_001253
C07207
C9H13N3O3
CCRIS 692
CHEBI:10101
CHEMBL853
CID24066
CPD000058253
Cytidine, 2',3'-dideoxy- & Colony-stimulating factor
Cytidine, 2',3'-dideoxy- & Interferon.alpha.
D 5782
D00412
D3581
D5782_SIGMA
DB00943
ddC
DDC
ddC & GM-CSF
ddC & IFN.alpha.
ddC & Interferon.alpha.
ddC & NP (from PHCA or HSA)
ddC & sCD4
ddC (Antiviral)
DDC (Antiviral)
DDC (DDC)
ddCyd
DDCYD
Dideoxycytidine
DS-4152 & ddC
EU-0100360
Hivid
HIVID
|
Hivid (TN)
HIVID roche
Hivid(TM)
Hivid, Dideoxycytidine, NSC 606170, Zalcitabine
HMS1548B19
HMS1571O15
HMS2051H18
HMS2090C12
Hoffman-la roche brand OF zalcitabine
HSDB 7156
Interferon AD + ddC
KS-1130
Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine
Lopac0_000360
LS-1645
MLS000069636
MLS000759540
MLS001055363
MLS001424210
MolPort-002-885-873
NCGC00090705-01
NCGC00090705-02
NCGC00090705-03
NCGC00090705-05
NCGC00090705-06
NCGC00090705-07
NCGC00090705-10
NCGC00179242-01
NSC 606170
NSC606170
NSC-606170
PC-SOD & ddC
Prestwick0_001037
Prestwick1_001037
Prestwick2_001037
Prestwick3_001037
Ro 24-2027/000
Ro-24-2027/000
Roche brand OF zalcitabine
S1719_Selleck
SAM001246779
SMR000058253
SPBio_003104
SRI-7707
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
TimTec1_004969
UNII-6L3XT8CB3I
UPCMLD-DP115
UPCMLD-DP115:001
zalcitabine
Zalcitabine
Zalcitabine (JAN/USP/INN)
Zalcitabine [USAN:INN:BAN]
Zalcitibine
ZINC00039906
|
|
| 16 |
|
Metformin |
Approved |
Phase 4 |
|
657-24-9 |
14219 4091 |
|
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
| 17 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687 |
|
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
Apo pravastatin
Apo-pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
BIDD:GT0773
BRD-K60511616-236-01-4
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
FT-0082682
Juste brand OF pravastatin sodium
KS-5015
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
LS-94713
Mevalothin
Mevalotin
Mevastatin
Mevinolin
|
nchembio.301-comp7
nchembio790-comp15
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
pravastatin
Pravastatin
Pravastatin (INN)
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin Sodium
Pravastatin sodium salt
Pravastatin Sodium Salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin tert-Octylamine Salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS 431
RMS-431
Sankyo brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
SQ-31,000
Squibb brand OF pravastatin sodium
UNII-KXO2KT9N0G
Vasten
|
|
| 18 |
|
Insulin glulisine |
Approved |
Phase 4 |
|
207748-29-6 |
|
|
Synonyms:
Insulin glulisine
Insulin Glulisine (recombinant DNA origin)
|
Insulin glulisine recombinant
Insulina glulisina
|
|
| 19 |
|
Zinc |
Approved, Investigational |
Phase 4 |
|
7440-66-6 |
32051 |
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
| 20 |
|
Tesamorelin |
Approved, Investigational |
Phase 4 |
|
218949-48-5 |
|
|
Synonyms:
GHRH(1-44)
N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet)
|
|
|
| 21 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
|
Synonyms:
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(-)-SddC
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
3'-Thia-2',3'-dideoxycytidine
480434-79-5
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH189
BCH-189
BCH-790
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
BIDD:GT0033
Bio-0652
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
|
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR109714X
GR-109714X
Hepitec
Heptivir
Heptodin
Heptovir
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
L0217
Lamivir
Lamivudin
Lamivudina
lamivudine
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [Usan:Ban:Inn]
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine, (2S-cis)-isomer
Lamivudine, (2S-cis)-Isomer
Lamivudinum
LMV
LS-2107
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
Zeffix
Zefix
ZINC00012346
Î’-L-2',3'-dideoxy-3'-thiacytidine
Î’-L-3'-thia-2',3'-dideoxycytidine
|
|
| 22 |
|
Zidovudine |
Approved |
Phase 4 |
|
30516-87-1 |
35370 |
|
Synonyms:
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3' Azido 2',3' dideoxythymidine
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3&prime
30516-87-1
399024-19-2
3'-Azido-2',3'-dideoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3-Azido-3-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-azido-3'-deoxythymidine, AZT
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
antiviral
Antiviral azt
Antiviral AZT
Apo-Zidovudine
-Azido-3&prime
azidodeoxythymidine
Azidothymidine
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT & SST
AZT (antiviral)
AZT (Antiviral)
AZT antiviral
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT, antiviral
AZT, Antiviral
AZT+PRO 140
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW a509U
BW A509U
BWA 509u
BWA 509U
BW-A 509U
BWA509u
BWA-509u
BWA509U
BWA-509U
BW-A509U
BW-A-509U
C07210
CCRIS 105
|
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
Compound S
Cpd S
CPD000058351
D00413
D015215
DB00495
-deoxythymidine
DivK1c_000524
DRG-0004
DS-4152 & AZT
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
Liposomal AZT-SN-1
Liposomal AZT-SN-3
LS-1159
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
Novo-Azt
NSC 602670
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
Retrovir
Retrovir (TN)
Retrovir(TM)
rIFN-beta seron & AZT
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
Spectrum_001348
SPECTRUM1502109
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
STK801891
UNII-4B9XT59T7S
ZDV
zidovudin
Zidovudin
Zidovudina
Zidovudina [Spanish]
zidovudine
Zidovudine
Zidovudine (JAN/USP/INN)
ZIDOVUDINE [AZT]
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine EP III
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
ZINC03779042
ZVD
|
|
| 23 |
|
Abacavir |
Approved, Investigational |
Phase 4 |
|
136470-78-5 |
65140 441300 |
|
Synonyms:
(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(+/-)-Abacavir
(1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
136470-78-5
1592U89
168146-84-7
abacavir
Abacavir
Abacavir (INN)
Abacavir [INN]
Abacavir succinate
Abacavir sulfate
ABC
|
AC1L9AXG
Bio-0001
C07624
CHEBI:421707
CHEMBL1380
CID441300
D07057
DB01048
Epzicom
NCGC00164560-01
NCGC00164560-02
NSC742406
Trizivir
Ziagen
Ziagen (TM)(*Succinate salt*)
ZINC02015928
|
|
| 24 |
|
Darunavir |
Approved |
Phase 4 |
|
635728-49-3, 206361-99-1 |
213039 |
|
Synonyms:
(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester
(3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamic acid
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulphanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulphanilamido)propyl)carbamic acid
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamATE
(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamic acid
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulphonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulphonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamic acid
(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulphonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulphonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulphonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulphonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
114, TMC
206361-99-1
2f80
2f81
2f8g
2hs1
|
2hs2
2idw
2ien
3bvb
3cyw
3d1z
3d20
618109-00-5
AC1L4U4V
AIDS073035
Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
CHEBI:367163
CHEMBL1323
CID213039
D03656
Darunavir
Darunavir (USAN/INN)
Darunavir [USAN]
Darunavir ethanolate
Darunavirum
Darunavirum [INN-latin]
Darunavirum [INN-Latin]
DB01264
Ethanolate, darunavir
LS-187026
LS-187772
LS-191295
MolPort-003-846-141
N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
N-((1S,2R)-3-(((4-Aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
Prezista
Prezista(TM)
TMC 114
TMC114
TMC-114
UIC 94017
UIC-94017
UIC-96017
UNII-YO603Y8113
|
|
| 25 |
|
Dolutegravir |
Approved |
Phase 4 |
|
1051375-16-6 |
54726191 |
|
Synonyms:
|
| 26 |
|
Cobicistat |
Approved |
Phase 4 |
|
1004316-88-4 |
|
|
Synonyms:
1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate
|
|
|
| 27 |
|
Rilpivirine |
Approved |
Phase 4 |
|
500287-72-9 |
6451164 |
|
Synonyms:
278, TMC
4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
HCL, Rilpivirine
Hydrochloride, rilpivirine
Rilpivirina
|
Rilpivirine
Rilpivirine HCL
Rilpivirine hydrochloride
TMC 278
TMC278
TMC-278
|
|
| 28 |
|
Mannitol |
Approved, Investigational |
Phase 4 |
|
69-65-8 |
453 6251 |
|
Synonyms:
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
Bronchitol
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
Tobrex
UNII-3OWL53L36A
ZINC02041302
|
|
| 29 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 30 |
|
Thiamine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
70-16-6, 59-43-8 |
1130 |
|
Synonyms:
[5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride
100660-17-1
115461-66-0
1sbr
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride
3-(4-AMINO-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride
55463-15-5
57777-32-9
59-43-8
67-03-8
AC-11683
AC1L1ASK
AC1L1LOC
AC1LAODT
AC1Q4V9Q
AI3-18993
AKOS000668650
Aneurin
Aneurine
Antiberiberi factor
Apatate drape
Apate drops
AR-1L8201
B-Amin
BAS 00266240
Beatine
Bedome
Begiolan
Beivon
Benerva
Bequin
Berin
Betabion
Betalin S
Betaxin
Bethiamin
Bethiazine
Beuion
Bevitex
Bevitine
Bewon
Biamine
Bithiamin
Biuno
Bivatin
Bivita
bmse000274
BPBio1_000686
BSPBio_000622
C00378
C12H17N4OS
CCRIS 1906
CCRIS 5823
Cernevit-12
CHEBI:18385
CHEBI:33283
CHEBI:49105
CHEMBL1547
CHEMBL1588
Chloride-hydrochloride salt of thiamine
CID1130
CID517305
CID6042
Clotiamina
D08580
DB00152
EINECS 200-425-3
EINECS 200-641-8
Eskapen
Eskaphen
FEMA No. 3322
HSDB 220
Hybee
|
I14-14339
Lixa-beta
LS-3226
LT00233141
Metabolin
MLS001304099
MolPort-000-722-048
MolPort-001-920-086
MolPort-002-052-059
Mononitrate, thiamine
nchembio.121-comp5
NChemBio.2007.13-comp10
NSC 36226
NSC36226
Oryzanin
Oryzanine
Prestwick0_000631
Prestwick1_000631
Prestwick2_000631
Prestwick3_000631
SBB058094
Slowten
SMP1_000084
SMR000718788
SPBio_002841
ST095175
THD
Thiadoxine
thiamin
Thiamin
Thiamin dichloride
THIAMIN, VITAMIN B1
Thiaminal
thiamine
Thiamine
Thiamine (INN)
Thiamine [INN:BAN]
Thiamine chloride
Thiamine chloride hydrochloride
Thiamine dichloride
Thiamine HCL
Thiamine hydrochloride [JAN]
Thiamine monochloride
Thiamine monohydrochloride
Thiamine mononitrate
thiamine(1+)
thiamine(1+) ion
Thiamine(1+) ion
Thiamine, chloride
Thiamine, chloride, hydrochloride
Thiamine, monohydrochloride
thiaminium
Thiaminium
Thiaminium chloride hydrochloride
Thiaminum
Thiaminum [INN-Latin]
Thiamol
Thiavit
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1)
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride
Tiamidon
Tiamina
Tiamina [INN-Spanish]
Tiaminal
TimTec1_000613
Trophite
UNII-X66NSO3N35
Vetalin S
VIB
Vinothiam
Vitamin b 1
vitamin B1
Vitamin b1
Vitamin B1
Vitamin B1 (TN)
Vitamin B1 hydrochloride (VAN)
vitamin b1(thiamine)
Vitaneurin
Vitaneuron
ZINC00049153
|
|
| 31 |
|
Riboflavin |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
83-88-5 |
493570 |
|
Synonyms:
(-)-Riboflavin
1-Deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-D-ribitol
1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol
6,7-Dimethyl-9-D-ribitylisoalloxazine
6,7-Dimethyl-9-ribitylisoalloxazine
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)-benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine
7,8-Dimethyl-10-ribitylisoalloxazine
Beflavin
Beflavine
Benzo[g]pteridine riboflavin deriv.
Bisulase
e 101
e101
Flavaxin
Flavin BB
Flaxain
FOOD Yellow 15
Hyre
Lactobene
Lactoflavin
|
Lactoflavine
Ribipca
Ribocrisina
Riboderm
Riboflavin
Riboflavina
Riboflavine
RIBOFLAVINE
Riboflavinum
Ribosyn
Ribotone
Ribovel
Russupteridine yellow III
San yellow b
Vitaflavine
Vitamin b 2
Vitamin b2
Vitamin B2
Vitamin Bi
Vitamin g
Vitamin G
Vitasan b2
|
|
| 32 |
|
Tenofovir |
Experimental, Investigational |
Phase 4 |
|
147127-20-6 |
464205 |
|
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
147127-20-6
206184-49-8
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
AC1LA9BO
AC-760
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GNA & Tenofovir
|
GS 1275
GS 1278
GS1278
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
PMPA
PMPA-(R)
S1401_Selleck
TDF
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TFV
UNII-99YXE507IL
Viread
Viread, Tenofovir
|
|
| 33 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
| 34 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
| 35 |
|
Atazanavir Sulfate |
|
Phase 4 |
|
|
|
| 36 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
| 37 |
|
Antitubercular Agents |
|
Phase 4 |
|
|
|
| 38 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
| 39 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
| 40 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
| 41 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
| 42 |
|
Micronutrients |
|
Phase 4 |
|
|
|
| 43 |
|
Nutrients |
|
Phase 4 |
|
|
|
| 44 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
| 45 |
|
Trace Elements |
|
Phase 4 |
|
|
|
| 46 |
|
Vitamins |
|
Phase 4 |
|
|
|
| 47 |
|
Folate |
|
Phase 4 |
|
|
|
| 48 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
| 49 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
| 50 |
|
carnitine |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 153)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. |
Unknown status |
NCT00135460 |
Phase 4 |
nucleoside analogue sparing HAART regimen |
| 2 |
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) |
Unknown status |
NCT00122226 |
Phase 4 |
Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine |
| 3 |
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks |
Unknown status |
NCT00426296 |
Phase 4 |
atazanavir (Reyataz);ritonavir (Norvir) |
| 4 |
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART) |
Completed |
NCT00119769 |
Phase 4 |
Placebo;Genotropin (human recombinant Growth hormone) |
| 5 |
A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy. |
Completed |
NCT00389194 |
Phase 4 |
continuing AZT+3TC or switching AZT+3TC to TDF+ FTC |
| 6 |
A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen. |
Completed |
NCT00389402 |
Phase 4 |
saquinavir/ritonavir;atazanavir/ritonavir |
| 7 |
A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study) |
Completed |
NCT00135356 |
Phase 4 |
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) |
| 8 |
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time |
Completed |
NCT00192660 |
Phase 4 |
Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20) |
| 9 |
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities |
Completed |
NCT00139178 |
Phase 4 |
Different HAART regimens |
| 10 |
Comparison of Strategies of Interruption/Reinitiation of Antiretroviral Therapy in Response to Immunologic/Virologic Changes in HIV-Infected Patients With Lipodystrophy. |
Completed |
NCT00646984 |
Phase 4 |
Standard continuous antiretroviral therapy;CD-4 guided therapy interruption;Viral load driven treatment interruption |
| 11 |
The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients |
Completed |
NCT00006190 |
Phase 4 |
Nelfinavir mesylate;Stavudine;Lamivudine;Efavirenz |
| 12 |
Mecahnisms of Lipodystrophy in HIV-Infected Patients |
Completed |
NCT00457665 |
Phase 4 |
Nelfinavir;Efavirenz |
| 13 |
Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) |
Completed |
NCT00005764 |
Phase 4 |
Lamivudine/Zidovudine;Abacavir sulfate;Lamivudine |
| 14 |
Metabolic Abnormalities in HIV-infected Persons |
Completed |
NCT01612858 |
Phase 4 |
Metformin;Pioglitazone |
| 15 |
A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV |
Completed |
NCT00227500 |
Phase 4 |
Pravastatin |
| 16 |
A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism |
Completed |
NCT00192621 |
Phase 4 |
Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr]) |
| 17 |
Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation. |
Completed |
NCT00202228 |
Phase 4 |
cofactor supplementation (thiamine, riboflavin, L-carnitine) |
| 18 |
Yoga for the Management of HIV-Metabolic Syndromes |
Completed |
NCT00627380 |
Phase 4 |
|
| 19 |
CT to Assess the Effect on the Subcutaneous Fat of Change of EFV for LPV/r in HIV-infected Patients Who Developed Lipoatrophy and Remains Despite Treatment With Efavirenz and Fixed-dose Combination of no Thymidine Nucleoside Analogues. |
Completed |
NCT00978237 |
Phase 4 |
EFV;LPV/r |
| 20 |
Lipoatrophy in Children, Adolescents and Adults With Modern Treatment Modalities: is There a Beneficial Effect of Insulin Glulisine? |
Completed |
NCT02914886 |
Phase 4 |
Apidra;current insulin |
| 21 |
A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir |
Completed |
NCT00865007 |
Phase 4 |
Monotherapy (Lopinavir/ritonavir);Monotherapy (Lopinavir/ritonavir) + ABC/3TC |
| 22 |
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV |
Recruiting |
NCT04340388 |
Phase 4 |
Dolutegravir 50 MG;Antiretroviral/Anti HIV |
| 23 |
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy |
Recruiting |
NCT04026178 |
Phase 4 |
Metreleptin |
| 24 |
Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy |
Recruiting |
NCT03226821 |
Phase 4 |
Tesamorelin |
| 25 |
Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121) |
Terminated |
NCT00122668 |
Phase 4 |
non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor |
| 26 |
A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH) |
Terminated |
NCT00126308 |
Phase 4 |
|
| 27 |
A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study |
Terminated |
NCT00122655 |
Phase 4 |
non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors |
| 28 |
A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptraâ„¢ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy |
Withdrawn |
NCT00360139 |
Phase 4 |
|
| 29 |
Effects of an Exercise Program on Metabolic Parameters of Patients With a HIV Infection. |
Unknown status |
NCT00910936 |
Phase 2, Phase 3 |
|
| 30 |
Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE |
Completed |
NCT00383734 |
Phase 3 |
|
| 31 |
Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy |
Completed |
NCT00896298 |
Phase 2, Phase 3 |
Leptin;Placebo |
| 32 |
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat Accumulation |
Completed |
NCT00608023 |
Phase 3 |
Tesamorelin;Placebo for Tesamorelin |
| 33 |
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS |
Completed |
NCT00082628 |
Phase 3 |
Placebo;Serostim® 4 mg;Serostim® 2 mg |
| 34 |
Open Label, Multicenter, Single Arm Trial of the Safety and Efficacy of Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy : THE LIPOPHILL TRIAL |
Completed |
NCT01077765 |
Phase 3 |
|
| 35 |
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation |
Completed |
NCT00123253 |
Phase 3 |
TH9507 |
| 36 |
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy |
Completed |
NCT00307164 |
Phase 2, Phase 3 |
NucleomaxX;NucleomaxX placebo |
| 37 |
A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities |
Completed |
NCT00006412 |
Phase 3 |
Pravastatin sodium;Fenofibrate |
| 38 |
Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy |
Recruiting |
NCT02262806 |
Phase 3 |
Metreleptin |
| 39 |
Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy |
Recruiting |
NCT02262832 |
Phase 3 |
Metreleptin |
| 40 |
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS |
Recruiting |
NCT04517253 |
Phase 2, Phase 3 |
Baricitinib |
| 41 |
A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance |
Recruiting |
NCT04018365 |
Phase 3 |
Empagliflozin Tablets |
| 42 |
A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02) |
Recruiting |
NCT04221152 |
Phase 3 |
Empagliflozin Tablets |
| 43 |
A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy |
Active, not recruiting |
NCT02527343 |
Phase 2, Phase 3 |
volanesorsen;Placebo |
| 44 |
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study |
Terminated |
NCT00148850 |
Phase 3 |
Pioglitazone |
| 45 |
Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients |
Completed |
NCT00140244 |
Phase 2 |
r-metHuLeptin;Placebo |
| 46 |
Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients |
Completed |
NCT00457639 |
Phase 2 |
Cholic Acid |
| 47 |
Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation |
Completed |
NCT00656175 |
Phase 2 |
raltegravir |
| 48 |
A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART) |
Completed |
NCT00647946 |
Phase 2 |
tenofovir DF;abacavir 300mg twice daily |
| 49 |
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy |
Completed |
NCT03514420 |
Phase 2 |
AKCEA-ANGPTL3-LRX |
| 50 |
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy |
Completed |
NCT02654977 |
Phase 2 |
Metreleptin |
Search
NIH Clinical Center
for Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome
Inferred drug relations via
UMLS
71
/
NDF-RT
51
:
Cochrane evidence based reviews: lipodystrophy
|
Rare otorhinolaryngological diseases 
